Demonstrating that statin regulation of RyR1 and HMG‐CoA reductase are separable effects will allow the role of RyR1 in statin‐induced myopathy to be further elucidated by the tool compounds we have identified, allowing development of effective cardioprotective statins with improved patient tolerance. This evidence concerns the gene RYR1 and myopathy.